Evaluation of an Antimicrobial Stewardship Program for Wound and Burn Care in Three Hospitals in Nepal
Abstract
:1. Introduction
2. Results
2.1. Patient Chart Data: Demographics
2.2. Patient Chart Data: Antibiotic Use at Baseline and Post-Intervention
3. Discussion
4. Materials and Methods
4.1. Study Sites
4.2. Study Population
4.3. Data Collection
4.3.1. Patient Chart Data
4.3.2. Physician Logbook Data
4.4. Data Management and Analysis
4.5. Ethical Review
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Allegranzi, B.; Nejad, S.B.; Combescure, C.; Graafmans, W.; Attar, H.; Donaldson, L.; Pittet, D. Burden of endemic health-care-associated infection in developing countries: Systematic review and meta-analysis. Lancet 2011, 377, 228–241. [Google Scholar] [CrossRef]
- Davey, P.; Brown, E.; Fenelon, L.; Finch, R.; Gould, I.; Hartman, G.; Holmes, A.; Ramsay, C.; Taylor, E.; Wilcox, M.; et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst. Rev. 2005, 4, CD003543. [Google Scholar] [CrossRef]
- Arnold, F.W.; McDonald, L.C.; Smith, R.S.; Newman, D.; Ramirez, J.A. Improving Antimicrobial Use in the Hospital Setting by Providing Usage Feedback to Prescribing Physicians. Infect. Control. Hosp. Epidemiol. 2006, 27, 378–382. [Google Scholar] [CrossRef] [PubMed]
- Van Dijck, C.; Vlieghe, E.; Cox, J.A. Antibiotic stewardship interventions in hospitals in low-and middle-income countries: A systematic review. Bull. World Health Organ. 2018, 96, 266–280. [Google Scholar] [CrossRef] [PubMed]
- Joshi, R.D.; Zervos, M.; Kaljee, L.; Shrestha, B.; Maki, G.; Prentiss, T.; Bajracharya, D.C.; Karki, K.; Joshi, N.; Rai, S.M. Evaluation of a Hospital-Based Post-Prescription Review and Feedback Pilot in Kathmandu, Nepal. Am. J. Trop. Med. Hyg. 2019, 101, 923–928. [Google Scholar] [CrossRef] [PubMed]
- Gosselin, R.A. Injuries: The neglected burden in developing countries. Bull. World Health Organ. 2009, 87, 246. [Google Scholar] [CrossRef] [PubMed]
- Gupta, S.; Wong, E.G.; Nepal, S.; Shrestha, S.; Kushner, A.L.; Nwomeh, B.C.; Wren, S.M. Injury prevalence and causality in developing nations: Results from a countrywide population-based survey in Nepal. Surgery 2015, 157, 843–849. [Google Scholar] [CrossRef] [PubMed]
- Tripathee, S.; Basnet, S.J. Epidemiology of burn injuries in Nepal: A systemic review. Burn. Trauma 2017, 5, 10. [Google Scholar] [CrossRef]
- Krishnan, P.L.; Frew, Q.; Green, A.; Martin, R.; Dziewulski, P. Cause of death and correlation with autopsy findings in burns patients. Burns 2013, 39, 583–588. [Google Scholar] [CrossRef] [PubMed]
- Bloemsma, G.; Dokter, J.; Boxma, H.; Oen, I. Mortality and causes of death in a burn centre. Burns 2008, 34, 1103–1107. [Google Scholar] [CrossRef] [PubMed]
- Lachiewicz, A.M.; Hauck, C.G.; Weber, D.J.; Cairns, B.A.; Van Duin, D. Bacterial Infections After Burn Injuries: Impact of Multidrug Resistance. Clin. Infect. Dis. 2017, 65, 2130–2136. [Google Scholar] [CrossRef] [PubMed]
- Sharma, K.; Thanbuana, B.T.; Gupta, A.K.; Rajkumari, N.; Mathur, P.; Gunjiyal, J.; Misra, M.C. A prospective study of wound infection among post-discharge patients at a level 1 trauma centre of India. Indian J. Med. Microbiol. 2016, 34, 198–201. [Google Scholar] [CrossRef] [PubMed]
- Bhangu, A.; Ademuyiwa, A.O.; Aguilera, M.L.; Alexander, P.; Al-Saqqa, S.W.; Borda-Luque, G.; Costas-Chavarri, A.; Drake, T.M.; Ntirenganya, F.; Fitzgerald, J.E.; et al. Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: A prospective, international, multicentre cohort study. Lancet Infect. Dis. 2018, 18, 516–525. [Google Scholar] [CrossRef] [Green Version]
- Phuyal, K.; Ogada, E.A.; Bendell, R.; Price, P.E.; Potokar, T. Burns in Nepal: A participatory, community survey of burn cases and knowledge, attitudes and practices to burn care and prevention in three rural municipalities. BMJ Open 2020, 10, e033071. [Google Scholar] [CrossRef] [PubMed]
- Karki, B.; Rai, S.M.; Nakarmi, K.K.; Basnet, S.J.; Magar, M.G.; Nagarkoti, K.K.; Thapa, S. Clinical Epidemiology of Acute Burn Injuries at Nepal Cleft and Burn Centre, Kathmandu, Nepal. Ann. Plast. Surg. 2018, 80, S95–S97. [Google Scholar] [CrossRef] [PubMed]
- Viswanathan, V.; Pendsey, S.; Radhakrishnan, C.; Rege, T.D.; Ahdal, J.; Jain, R. Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infection in India: A Growing Menace. Int. J. Low. Extrem. Wounds 2019, 18, 236–246. [Google Scholar] [CrossRef] [PubMed]
- Bahemia, I.; Muganza, A.; Moore, R.E.; Sahid, F.; Menezes, C. Microbiology and antibiotic resistance in severe burns patients: A 5 year review in an adult burns unit. Burns 2015, 41, 1536–1542. [Google Scholar] [CrossRef] [PubMed]
- WHO. Global Action Plan on Antimicrobial Resistance. Available online: https://www.who.int/antimicrobial-resistance/global-action-plan/en/ (accessed on 6 October 2020).
- Pujji, O.J.S.; Nakarmi, K.K.; Shrestha, B.; Rai, S.M.; Jeffery, S.L.A. The Bacteriological Profile of Burn Wound Infections at a Tertiary Burns Center in Nepal. J. Burn. Care Res. 2019, 40, 838–845. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gyawali, S.; Shandar Ravi, P.; Saha, A.; Mohan, L. Study of prescription injectable drugs and intravenous fluids to inpatients in a teaching hospital in Nepal. McGill J. Med. 2009, 12, 13–20. [Google Scholar] [PubMed]
- Harris, P.A.; Taylor, R.; Minor, B.L.; Elliott, V.; Fernandez, M.; O’Neal, L.; McLeod, L.; Delacqua, G.; Delacqua, F.; Kirby, J.; et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 2019, 95, 103208. [Google Scholar] [CrossRef] [PubMed]
Demographic Characteristics | Baseline | Post-Intervention | p-Value | |
---|---|---|---|---|
Gender | Female | 38.6% (93) | 38.6% (91) | 0.995 |
Mean age (SD) | 39.2 (17.6) Range: 16–83 | 37.4 (17.4) Range: 15–88 | 0.252 | |
Hospital | Kathmandu Model | 33.2% (80) | 31.5% (74) | 0.837 |
Kirtipur | 32.4% (78) | 34.9% (82) | ||
Pokhara | 34.4% (83) | 33.6% (79) | ||
Ward | Surgery | 67.4% (161) | 65.5% (154) | <0.001 |
Plastic and reconstructive surgery | 22.6% (54) | 8.9% (21) | ||
Burn unit | 10.0% (24) | 25.5% (60) | ||
Mean length of hospital stay (days) (SD) by ward | Total | 8.0 (5.9) Range: 3–48 | 6.4 (6.2) Range: 3–70 | 0.006 |
Surgery | 6.7 (3.7) Range: 3–27 | 6.6 (7.0) Range: 3–70 | 0.788 | |
Plastic and reconstructive surgery | 8.3 (5.4) Range: 3–24 | 6.3 (6.0) Range: 3–27 | 0.181 | |
Burn unit | 15.2 (11.2) Range: 3–48 | 6.1 (4.1) Range: 3–16 | <0.001 |
Site | Antibiotic Delivery & Class | Baseline DOT/1000 PD (N) | Post-Intervention DOT/1000 PD (N) | p-Value |
---|---|---|---|---|
TOTAL SITES | Intravenous antibiotics | 1165 (222) | 1114 (227) | 0.67 |
Oral antibiotics | 101 (46) | 75 (31) | 0.09 | |
Penicillin | 301 (91) | 241 (70) | 0.02 | |
Cephalosporin | 525 (167) | 454 (167) | 0.04 | |
Metronidazole | 75 (30) | 160 (56) | <0.001 | |
Quinolone | 46 (17) | 72 (24) | 0.01 | |
Aminoglycoside | 266 (84) | 117 (39) | <0.001 | |
Other course | 57 (16) | 177 (53) | <0.001 | |
KIRTIPUR | Intravenous antibiotics | 292 (70) | 304 (77) | 0.56 |
Oral antibiotics | 64 (27) | 37 (10) | 0.004 | |
Penicillin | 49 (15) | 61 (19) | 0.30 | |
Cephalosporin | 264 (71) | 228 (71) | <0.001 | |
Metronidazole | 10 (4) | 30 (10) | 0.002 | |
Quinolone | 9 (30) | 14 (5) | 0.40 | |
Aminoglycoside | 8 (40 | 16 (4) | 0.15 | |
Other course | 18 (5) | 16 (4) | 0.73 | |
KATHMANDU MODEL | Intravenous antibiotics | 289 (70) | 354 (72) | 0.80 |
Oral antibiotics | 29 (17) | 32 (18) | 0.80 | |
Penicillin | 63 (18) | 54 (17) | 0.04 | |
Cephalosporin | 125 (63) | 144 (61) | 0.59 | |
Metronidazole | 42 (18) | 112 (42) | <0.001 | |
Quinolone | 37 (14) | 24 (9) | 0.02 | |
Aminoglycoside | 34 (21) | 40 (16) | 0.90 | |
Other course | 20 (6) | 16 (9) | 0.23 | |
POKHARA | Intravenous antibiotics | 584 (82) | 436 (77) | 0.12 |
Oral antibiotics | 8 (2) | 5 (3) | 0.37 | |
Penicillin | 189 (58) | 127 (34) | 0.22 | |
Cephalosporin | 136 (33) | 76 (35) | 0.02 | |
Metronidazole | 24 (8) | 15 (4) | 0.62 | |
Quinolone | 0 | 33 (9) | <0.001 | |
Aminoglycoside | 224 (59) | 56 (18) | <0.001 | |
Other course | 19 (5) | 142 (41) | <0.001 |
Site | Review Criteria | Baseline | Post-Intervention | p-Value |
---|---|---|---|---|
TOTAL SITES | Was the antibiotics course justified? (Yes) | 34.9% (84) | 78.0% (184) | <0.001 |
Were antibiotics de-escalated? (Yes) | 28.0% (51) | 85.9% (167) | <0.001 | |
Was the treatment rationale documented correctly? (Yes) | 33.3% (62) | 77.7% (146) | <0.001 | |
Were guidelines followed within the first 72 h of therapy? (Yes) | 37.9% (67) | 82.2% (143) | <0.001 | |
Were recommendations followed for definitive therapy? (Yes) | 29.4% (50) | 82.8% (154) | <0.001 | |
KIRTIPUR | Was the antibiotics course justified? (Yes) | 33.3% (26) | 70.7% (58) | <0.001 |
Were antibiotics de-escalated? (Yes) | 41.8% (28) | 87.5% (56) | <0.001 | |
Was the treatment rationale documented correctly? (Yes) | 27.4% (20) | 68.6% (48) | <0.001 | |
Were guidelines followed within the first 72 h of therapy? (Yes) | 30.8% (20) | 78.6% (44) | <0.001 | |
Were recommendations followed for definitive therapy? (Yes) | 27.8% (20) | 77.2% (44) | <0.001 | |
KATHMANDU MODEL | Was the antibiotics course justified? (Yes) | 46.3% (37) | 77.0% (57) | <0.001 |
Were antibiotics de-escalated? (Yes) | 30.4% (21) | 78.6% (55) | <0.001 | |
Was the treatment rationale documented correctly? (Yes) | 53.5% (38) | 81.4% (57) | <0.001 | |
Were guidelines followed within the first 72 h of therapy? (Yes) | 63.0% (46) | 80.6% (54) | 0.016 | |
Were recommendations followed for definitive therapy? (Yes) | 46.2% (30) | 79.4% (54) | <0.001 | |
POKHARA | Was the antibiotics course justified? (Yes) | 25.3% (21) | 86.1% (68) | <0.001 |
Were antibiotics de-escalated? (Yes) | 4.3% (2) | 91.7% (55) | <0.001 | |
Was the treatment rationale documented correctly? (Yes) | 9.5% (4) | 85.4% (41) | <0.001 | |
Were guidelines followed within the first 72 h of therapy? (Yes) | 2.6% (1) | 88.2% (45) | <0.001 | |
Were recommendations followed for definitive therapy? (Yes) | 0 | 91.7% (55) | <0.001 |
Empiric Guidelines | |||
Diagnosis | Suspected Pathogen | Empiric Therapy | Duration of Therapy |
Abdominal infection, community-acquired (e.g., cholecystitis, cholangitis, diverticulitis, abscess); NOTE: add gentamicin if MDRO suspected or identified | Enterobacteriaceae Bacteroides sp. Enterococci Streptococci | Preferred: • Ceftriaxone IV 1 g q24h + metronidazole IV or PO 500 mg q8h • +/− gentamicin IV 5 mg/kg q24h Alternative: • piperacillin/tazobactam IV 4.5 g q6h • cefepime IV 2 g q12h + metronidazole IV or PO 500 mg q8h + IV 5mg/kg q24hr • imipenem IV 1g q8h Oral options for outpatient therapy: • ofloxacin PO 400 mg q12h + metronidazole PO 500 mg q12h • moxifloxacin PO 400 mg q24h | 4 days with adequate source control |
Suggested Definitive Guidelines | |||
Organism | Preferred Therapy | Alternative Therapy (Depending on Allergies and Susceptibilities) | |
Enterobacter spp. (AmpC-producing organism | Cefepime | Meropenem, colistin, tigecycline, trimethoprim/sulfamethoxazole, gentamicin, amikacin Consider combination therapy for extensively drug-resistant Acinetobacter | |
Suggested Duration of Antimicrobial Therapy Based on Indication | |||
Diagnosis | Duration of Therapy | Key References | |
Complicated intra-abdominal infection, community-acquired (appendicitis, cholecystitis, diverticulitis) | 4 to 7 days after adequate source control | Infectious Diseases Society of America Guidelines: http://www.idsociety.org/uploadedFiles/IDSA/GuidelinesPatient_Care/PDF_Library/Intraabdominal%20Infectin.pdf Other resources: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411162 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nauriyal, V.; Rai, S.M.; Joshi, R.D.; Thapa, B.B.; Kaljee, L.; Prentiss, T.; Maki, G.; Shrestha, B.; Bajracharya, D.C.; Karki, K.; et al. Evaluation of an Antimicrobial Stewardship Program for Wound and Burn Care in Three Hospitals in Nepal. Antibiotics 2020, 9, 914. https://doi.org/10.3390/antibiotics9120914
Nauriyal V, Rai SM, Joshi RD, Thapa BB, Kaljee L, Prentiss T, Maki G, Shrestha B, Bajracharya DC, Karki K, et al. Evaluation of an Antimicrobial Stewardship Program for Wound and Burn Care in Three Hospitals in Nepal. Antibiotics. 2020; 9(12):914. https://doi.org/10.3390/antibiotics9120914
Chicago/Turabian StyleNauriyal, Varidhi, Shankar Man Rai, Rajesh Dhoj Joshi, Buddhi Bahadur Thapa, Linda Kaljee, Tyler Prentiss, Gina Maki, Basudha Shrestha, Deepak C. Bajracharya, Kshitij Karki, and et al. 2020. "Evaluation of an Antimicrobial Stewardship Program for Wound and Burn Care in Three Hospitals in Nepal" Antibiotics 9, no. 12: 914. https://doi.org/10.3390/antibiotics9120914
APA StyleNauriyal, V., Rai, S. M., Joshi, R. D., Thapa, B. B., Kaljee, L., Prentiss, T., Maki, G., Shrestha, B., Bajracharya, D. C., Karki, K., Joshi, N., Acharya, A., Banstola, L., Poudel, S. R., Joshi, A., Dahal, A., Palikhe, N., Khadka, S., Giri, P., ... Zervos, M. (2020). Evaluation of an Antimicrobial Stewardship Program for Wound and Burn Care in Three Hospitals in Nepal. Antibiotics, 9(12), 914. https://doi.org/10.3390/antibiotics9120914